Table 1.
Descriptive characteristics of studies included in the integrative review
| N | % | ||
|---|---|---|---|
| Country | USA | 11 | 63.61.11 |
| USA and Canada | 1 | 5.26 | |
| Canada | 1 | 5.26 | |
| France, Germany, and Spain | 1 | 5.26 | |
| France | 1 | 5.26 | |
| Spain | 1 | 5.26 | |
| The Netherlands | 2 | 5.26 | |
| Singapore | 1 | 5.26 | |
| Study design | Quantitative | 12 | 57.89 |
| Qualitative | 5 | 27.78 | |
| Mixed | 2 | 10.53 | |
| Sample | Women only | 13 | 63.16 |
| Men only | 1 | 5.26 | |
| Any gender | 5 | 27.78 | |
| Outcome measurements | Recall/ understanding of the test result | 11 | 52.63 |
| Communication with healthcare providers | 8 | 44.44 | |
| Family communication on the rest result | 4 | 22.22 | |
| Emotional/psychological effects of test result | 10 | 52.63 | |
| Perception of cancer risks | 6 | 27.78 | |
| Screening and risk-reducing surgery decision making | 7 | 36.84 | |
| Type of genetic test | BRCA 1/2 genes | 10 | 47.37 |
| Lynch or single gene | 2 | 10.53 | |
| Multigene panel | 7 | 38.89 | |
| Results of sample | VUS only | 6 | 38.33 |
| PV or VUS | 4 | 21.05 | |
| Negative or VUS | 2 | 10.53 | |
| PV or VUS or Negative | 7 | 31.58 | |
| Publication date | 2000–2004 | 2 | 5.26 |
| 2005–2009 | 3 | 15.79 | |
| 2010–2014 | 3 | 15.79 | |
| 2014–2020 | 11 | 61.11 |